<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OncoTargets and Therapy</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26955283</article-id><article-id pub-id-type="pmc">4768887</article-id><article-id pub-id-type="doi">10.2147/OTT.S97896</article-id><article-id pub-id-type="publisher-id">ott-9-855</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Potential impact of <sup>18</sup>FDG-PET/CT on surgical approach for operable squamous cell cancer of middle-to-lower esophagus</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Sujing</given-names></name><xref ref-type="aff" rid="af1-ott-9-855">1</xref><xref ref-type="aff" rid="af2-ott-9-855">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Hui</given-names></name><xref ref-type="aff" rid="af1-ott-9-855">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Wanghu</given-names></name><xref ref-type="aff" rid="af3-ott-9-855">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Baijiang</given-names></name><xref ref-type="aff" rid="af4-ott-9-855">4</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="af5-ott-9-855">5</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Zhijun</given-names></name><xref ref-type="aff" rid="af6-ott-9-855">6</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Yong</given-names></name><xref ref-type="aff" rid="af3-ott-9-855">3</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Pingping</given-names></name><xref ref-type="aff" rid="af4-ott-9-855">4</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Jinming</given-names></name><xref ref-type="aff" rid="af1-ott-9-855">1</xref></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Hongbo</given-names></name><xref ref-type="aff" rid="af4-ott-9-855">4</xref><xref ref-type="corresp" rid="c1-ott-9-855"/></contrib></contrib-group><aff id="af1-ott-9-855"><label>1</label>Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People&#x02019;s Republic of China</aff><aff id="af2-ott-9-855"><label>2</label>Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People&#x02019;s Republic of China</aff><aff id="af3-ott-9-855"><label>3</label>Department of Radiology, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People&#x02019;s Republic of China</aff><aff id="af4-ott-9-855"><label>4</label>Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People&#x02019;s Republic of China</aff><aff id="af5-ott-9-855"><label>5</label>Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People&#x02019;s Republic of China</aff><aff id="af6-ott-9-855"><label>6</label>Department of Intensive Care Unit, Shandong Cancer Hospital and Institute, Jinan, Shandong Province, People&#x02019;s Republic of China</aff><author-notes><corresp id="c1-ott-9-855">Correspondence: Hongbo Guo, Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Jiyan Road 440, Jinan, Shandong Province 250117, People&#x02019;s Republic of China, Tel +86 531 6762 6230, Fax +86 531 8798 4079, Email <email>guomutong@126.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>22</day><month>2</month><year>2016</year></pub-date><volume>9</volume><fpage>855</fpage><lpage>862</lpage><permissions><copyright-statement>&#x000a9; 2016 Liu et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2016</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Background</title><p>Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT) is reported to have a significant advantage over CT for staging esophageal cancer (EC). However, whether PET/CT may play a useful role in guiding surgical approach remains undetermined.</p></sec><sec><title>Methods</title><p>Patients with potentially resectable squamous cell EC were randomized into either PET/CT group or CT group. The surgical data and survival outcomes were compared.</p></sec><sec><title>Results</title><p>Compared to the CT group, the right-sided approach was more frequently used (42.6% versus 25.5%, <italic>P</italic>=0.065) in the PET/CT group in order to allow surgical access to radiographically suspicious lymph nodes inaccessible from the left, thus enabling the removal of more involved lymph nodes (2.83 versus 1.76; <italic>P</italic>=0.039) as well as their stations (1.65 versus 1.08; <italic>P</italic>=0.042). Although the overall survival between the two groups was similar, the PET/CT group had a longer disease-free survival (DFS) than the CT group (27.1 months versus 18.9 months; <italic>P</italic>=0.019), especially in the subgroup of node-positive patients (22.5 months versus 13.5 months; <italic>P</italic>=0.02). Preoperative imaging arm was the only prognostic factor found to independently influence DFS.</p></sec><sec><title>Conclusion</title><p>For patients with middle-to-lower EC, surgical approaches directed by PET/CT may increase the likelihood of complete resection and affect DFS.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>esophagectomy</kwd><kwd>surgical approach</kwd><kwd>survival</kwd><kwd>esophageal cancer</kwd><kwd>PET/CT</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Most patients with esophageal cancer (EC) exhibit an advanced stage of disease at the time of diagnosis. Surgery remains the therapy of choice, provided a complete resection can be achieved (R0 resection). However, the high incidence of nodal involvement, present in approximately half of the patients, results in a 5-year survival rate of only 15%&#x02013;25% even after apparently curative surgery.<xref rid="b1-ott-9-855" ref-type="bibr">1</xref>&#x02013;<xref rid="b4-ott-9-855" ref-type="bibr">4</xref></p><p>Controversy remains regarding the optimal extent of lymph node (LN) resection during esophagectomy and whether systemic or extensive removal of LNs provides a survival benefit.<xref rid="b2-ott-9-855" ref-type="bibr">2</xref>,<xref rid="b5-ott-9-855" ref-type="bibr">5</xref> An extensive lymphadenectomy may offer a better chance of cure, but it is technically demanding and increases the risk of postoperative complications substantially.<xref rid="b4-ott-9-855" ref-type="bibr">4</xref>,<xref rid="b6-ott-9-855" ref-type="bibr">6</xref> Conversely, as in the People&#x02019;s Republic of China and most western countries, esophagectomy with LN sampling or less extensive lymphadenectomy via less invasive approaches still remains the mainstay of treatment and may reduce morbidity; the therapeutic outcomes appear to be comparable to operations via thoracotomy when combined with adjuvant therapy.<xref rid="b7-ott-9-855" ref-type="bibr">7</xref>&#x02013;<xref rid="b10-ott-9-855" ref-type="bibr">10</xref></p><p>Since there is no accepted standard to date as to the appropriate extent of LN resection,<xref rid="b4-ott-9-855" ref-type="bibr">4</xref> most surgeons take a compromise position, or a selective resection of LNs, to balance the potential benefit of resecting all diseases with the potential downside of three-field, complete lymphadenectomy.<xref rid="b7-ott-9-855" ref-type="bibr">7</xref>,<xref rid="b8-ott-9-855" ref-type="bibr">8</xref>,<xref rid="b10-ott-9-855" ref-type="bibr">10</xref></p><p>Meanwhile, more and more patients with EC in the People&#x02019;s Republic of China are aged, and many of them have poor cardiac or pulmonary function; the reduced injury seems to be important for them to recover from the surgery. If selective resection of LNs is undertaken, presurgical means of precisely localizing metastatic LNs would likely be quite important, as these studies could be used to determine the proper focus and extent of LN removal.<xref rid="b4-ott-9-855" ref-type="bibr">4</xref>,<xref rid="b11-ott-9-855" ref-type="bibr">11</xref></p><p>A number of radiologic modalities, including computed tomography (CT), endoscopic ultrasonography, and magnetic resonance imaging, have been used in defining metastatic spread of EC, but the diagnostic value is often limited,<xref rid="b12-ott-9-855" ref-type="bibr">12</xref>&#x02013;<xref rid="b15-ott-9-855" ref-type="bibr">15</xref> hampering the utility of these techniques in guiding the surgical approach. Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (<sup>18</sup>FDG) has generally been found to be more accurate than CT in detecting cancerous lesions. Several reports have been especially encouraging on the utility of PET in the direction of surgery for EC.<xref rid="b12-ott-9-855" ref-type="bibr">12</xref>&#x02013;<xref rid="b19-ott-9-855" ref-type="bibr">19</xref></p><p>Unlike other studies that mainly evaluate the diagnostic value of PET for EC, the current investigation is specifically focused on the practical application of PET/CT to surgery in comparison to that of CT. The aim of this study is to evaluate the impact of preoperative PET/CT (and CT) on surgical approaches for squamous cell cancer of the middle and lower esophagus. We also sought to determine whether surgical treatment based on the two imaging modalities yields different survival outcomes.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec sec-type="subjects"><title>Patients</title><p>Between April 2009 and September 2012, 210 patients with squamous cell cancer of the esophagus were evaluated for surgery (<xref ref-type="fig" rid="f1-ott-9-855">Figure 1</xref>). Exclusion criteria for this study included upper EC, prior treatment, uncontrolled diabetes mellitus, and inoperability due to medical reasons (eg, severe pulmonary or cardiac disease). Before surgery, all patients underwent history and physical examination, blood studies, electrocardiograms, abdominal ultrasonography, pulmonary function analyses, barium meals, magnetic resonance imaging, and other conventional workups (eg, bronchoscopy and endoscopic ultrasonography when indicated). Patients felt to be operable at that point (n=157) were then randomly divided into two groups: a PET/CT group and a CT group. According to the comprehensive evaluation of PET/CT or CT (including the above examinations), an additional 47 patients were considered unresectable after these studies based on M1 disease (including celiac and cervical LN involvement) or T4 disease, and the remaining 110 patients were taken to surgery. The study was approved by the local Shandong Cancer Hospital and Institute, and all patients signed the informed consent to participate.</p></sec><sec><title>PET/CT imaging</title><p>All patients fasted and rested for at least 6 hours before undergoing PET/CT (Discovery LS; GE Healthcare, Milwaukee, WI, USA). Serum glucose levels were measured to ensure that the results were &#x0003c;6.6 mmol/L. Sixty minutes after intravenous injection of 370 MBq (10 mCi) of <sup>18</sup>FDG, PET emission images were acquired from the level of the mid-skull to that of the proximal thigh for 5 minutes per field of view, each covering 14.5 cm, at an axial sampling thickness of 4.25 mm per slice. The spiral CT component was performed with an X-ray tube voltage peak of 120 kV, 90 mA, a 6:1 pitch, 0.8 seconds per rotation, and a slice thickness of 4.25 mm. A full-ring dedicated PET scan of the same axial range was acquired. Both PET and CT scans were obtained during normal tidal breathing. PET images were reconstructed with CT-derived attenuation correction using the ordered-subset expectation maximization algorithm. The attenuation-corrected PET images, CT images, and fused PET/CT images, subsequently displayed as coronal, sagittal, and transaxial slices, were viewed on a Xeleris workstation. The standardized uptake value (SUV) was calculated using the standard commercial software delivered with the PET/CT scanner.</p><p>All studies were interpreted jointly and in consensus by two experienced nuclear medicine physicians. Initially, the attenuation-corrected PET images were analyzed visually, and lesions with abnormal FDG uptake were considered indicative of malignancy. The CT and fused PET/CT images were reviewed together to amend the initial findings. When SUVs were &#x02265;2.5, the LNs were considered abnormal. There was no specific maximum SUV value that can be used to outstandingly represent benign or malignant disease.</p></sec><sec><title>Computed tomography</title><p>Spiral CT scans were obtained with Sensation 16 (Siemens Limited Company, Forcheim, Germany). After intravenous injection of 30 g of iodinated contrast (Ultravist 300, 300 mgI/mL; Bayer AG, Leverkusen, Germany), CT scanning was performed from the neck to the middle portion of both kidneys with 0.75 mm collimation, a pitch of 1.75, for 5 minutes per field of view, each covering 14.5 cm, at an axial sampling thickness of 4.25 mm per slice. All CT images were analyzed and in consensus by two radiologists. Nodal enlargement &#x0003e;1 cm in the maximum short-axis diameter was considered indicative of tumor involvement.</p></sec><sec><title>Surgical therapy</title><p>Surgery was usually performed within 1 week after imaging. Eligible patients underwent either a left- or right-sided approach for esophagectomy with lymphadenectomy. The choice of approach was left at the surgeon&#x02019;s discretion based on the locations of tumor and suspicious LNs by imaging. On the left, thoracotomy without laparotomy was used, and the anastomosis was placed either just below the aortic arch if the tumor is below the inferior pulmonary vein or in the cervix if the tumor is above the inferior pulmonary vein. On the right, the standard Ivor Lewis operation (laparotomy followed by repositioning and right thoracotomy) was used, the anastomosis was placed either at the apex of the thorax or in the neck. A circular stapler was routinely used for intrathoracic anastomosis, whereas a hand-sewn anastomosis was performed in case of cervicotomy. Enteral nutrition support through nasojejunal tube was initiated on the third day after operation.</p><p>The left-sided approach was the preferred approach since it was felt to be more straightforward and perhaps less morbid than the Ivor Lewis.<xref rid="b7-ott-9-855" ref-type="bibr">7</xref> However, LNs in the upper right mediastinal compartment, along recurrent nerves or bilaterally and adjacent to the celiac trunk, cannot be removed via the left-sided approach.<xref rid="b7-ott-9-855" ref-type="bibr">7</xref> Therefore, if CT or PET/CT suggested LN involvement in any of these areas, the Ivor Lewis approach was used.</p><p>All LNs were grouped according to their stations at pathology. Cervical nodes were scarce in this study since we excluded patients having cervical M1 LN disease preoperatively. The accuracy of detecting the involvement of nodal stations with each modality (PET/CT and CT, independently) was determined and compared with the pathological results. Patients with advanced pathological stages were further treated with chemotherapy (cisplatin and fluorouracil for four to six cycles; n=24) or chemoradiation (55&#x02013;65 Gy during 6&#x02013;7 weeks for radiation; n=49).</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>All patients were monitored through clinical visits or telephone interview up to a closeout date of December 1, 2014. Overall survival (OS) was measured from the date of surgery to that of death from any cause or to the time of the last follow-up. Disease-free survival (DFS) was measured from the date of surgery to that of a first relapse or death from any cause or to the time of the last visit without a developed recurrence. Survivals were estimated using the Kaplan&#x02013;Meier method (log-rank test). The Cox regression model was used to evaluate independent predictors affecting the survival. Only significant variables after univariate analysis (<italic>P</italic>&#x0003c;0.1) were included in multivariate analysis. Continuous and categorical variables were analyzed by independent sample <italic>t</italic>-test and chi-square test, respectively. <italic>P</italic>&#x0003c;0.05 was considered as significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 210 consecutive patients with EC were evaluated for possible participation in the study. Fifty-three were excluded, including 17 with a carcinoma above the level of carina, 6 with uncontrolled cardiac (n=4) or pulmonary disease (n=2), 21 who were felt to be unresectable, and nine who were surgically operable but refused surgery. The remaining 157 patients were randomized into two groups: PET/CT group (n=83) and CT group (n=74).</p><p>All patients in the PET/CT group displayed significant FDG uptake in their primary tumors, with a mean SUV of 12.3 (range, 3.8&#x02013;22.1). Twenty-seven patients were denied operation based on the PET/CT findings. The PET/CT of six patients suggested direct invasion to adjacent organs (T4), one detected a synchronous tumor at the hypopharynx, and 20 patients had distant metastatic lesions discovered in nonregional LNs (12), liver (4), lung (3), and adrenal (1). Among these lesions, eight LNs (biopsy in five and fine needle aspiration in three), two liver mass and two lung nodules were confirmed as a malignancy by histopathology, and others were all considered to be malignant on the tumor board and the patients were referred to palliative treatment.</p><p>In the CT group, 20 patients were denied surgery based on the CT findings. T4 tumors were detected in eight patients, and 12 patients had distant metastatic disease in nonregional LNs (7), liver (3), and lung (2). Among these lesions, all of the LNs were confirmed as a malignancy by biopsy, two liver mass and one lung nodule were confirmed by fine needle aspiration, and others were all considered to be malignant on the tumor board.</p><p>The remaining 110 patients were treated with surgery with curative intent. Among them, three patients (two in the PET/CT group and one in the CT group) were identified with unresectable disease at exploration, and two patients (1.8%) in the CT group died within 1 month after surgery. One patient died of a gastric leak in the thorax, and the other suffered from a sudden death that might be caused by pulmonary embolism. Thus, 105 patients (54 patients in the PET/CT group and 51 patients in the CT group) were suitable for analysis (<xref ref-type="table" rid="t1-ott-9-855">Table 1</xref>).</p><p>There were 86 men and 19 women, aged 37&#x02013;79 years (median 59 years). Among them, 68 patients had middle EC and 37 had a lower third tumor. There were no differences in case distributions between the PET/CT and CT groups (<xref ref-type="table" rid="t1-ott-9-855">Table 1</xref>).</p><p>Histology confirmed all primary tumors to be squamous cell carcinoma: 20 well-differentiated, 60 moderately differentiated, and 25 poorly differentiated tumors. Radical esophagectomy was performed in 51 (94.4%) patients of the PET/CT group and 47 (92.2%) patients of the CT group. A total of 69 patients underwent esophagectomy through left-sided transthoracic approach and 36 patients underwent right-sided thoracotomy, which consisted of Ivor Lewis procedure in 28 patients and Mckeown procedure in eight patients. Right-sided thoractomy tended to be more frequently used (42.6% versus 25.5%) in the PET/CT group compared to the CT group (<italic>P</italic>=0.065; <xref ref-type="table" rid="t2-ott-9-855">Table 2</xref>). Pathological stage was not significantly different between the PET/CT and the CT groups (<italic>P</italic>=0.834 for stage IIa, <italic>P</italic>=0.989 for stage IIb, <italic>P</italic>=0.118 for stage III, and <italic>P</italic>=0.471 for stage IV).</p><p>After surgery, recurrent laryngeal nerve injury occurred in seven patients, but the symptom of hoarseness resolved spontaneously within a few months in all the patients. Cervical anastomotic leak occurred in three cases. There were no intrathoracic anastomotic leaks. Chylothorax occurred in one patient. As previously stated, two postoperative deaths were already reported.</p><sec sec-type="results"><title>Results of the nodal resection</title><p>A total of 1058 LNs at 373 nodal stations were resected in the PET/CT group versus 896 LNs at 358 stations in the CT group (<italic>P</italic>=0.430 and <italic>P</italic>=0.831, respectively). Sixty-one patients (58.1%) had pathological LN involvement. Among these, 33 patients (61.1% of total 54) in the PET/CT group had 153 metastatic LNs at 89 nodal stations (two cervical, 62 mediastinal, and 25 abdominal), whereas 28 patients (54.9% of total 51) in the CT group had 90 involved LNs at 55 stations (one cervical, 39 mediastinal, and 15 abdominal) (<italic>P</italic>=0.007 for individual nodes and <italic>P</italic>=0.004 for stations). It appears that more invaded LNs and their stations were removed in the PET/CT group. The involved cervical nodes were occasionally found and removed when cervicotomy was performed for a cervical anastomosis.</p><p>The total number of LNs removed during surgery averaged 19.59 (6.91 stations) and 17.57 (7.02 stations) in the PET/CT and CT groups, respectively. Statistical analysis showed no significant difference between the groups (<italic>P</italic>=0.088 and <italic>P</italic>=0.724, respectively). However, PET/CT allowed a dissection of more positive LNs (mean 2.83 versus 1.76; <italic>P</italic>=0.039) as well as positive LN stations (average 1.65 versus 1.08; <italic>P</italic>=0.042) than CT. For node-positive patients, the percentage of invaded nodal stations that were totally removed in the PET/CT group (36.3%) was significantly higher than that in the CT group (27.9%) (<italic>P</italic>=0.038; <xref ref-type="table" rid="t3-ott-9-855">Table 3</xref>).</p></sec><sec><title>Assessment of nodal metastasis by imaging</title><p>On a station-based analysis, PET/CT displayed an overall sensitivity of 86.5% and an accuracy of 92.2% in the detection of the metastasis. CT showed a lower sensitivity of 67.3% (<italic>P</italic>=0.006) and an accuracy of 87.2% (<italic>P</italic>=0.024). Comparison of specificity between the two modalities (94% versus 90.8%; <italic>P</italic>=0.139) showed no statistically significant difference (<xref ref-type="table" rid="t4-ott-9-855">Table 4</xref>).</p></sec><sec><title>Survival outcome</title><p>Up to the closeout date, five patients were lost to follow-up. The mean follow-up period was 23 months, ranging from 5 months to 51.5 months. The estimated mean OS for the PET/CT group (28.4 months; 95% CI: 24.1&#x02013;32.7 months) was slightly higher than that for the CT group (25.7 months; 95% CI: 21.7&#x02013;29.6 months) but did not achieve statistical significance (<italic>P</italic>=0.38). However, the estimated mean DFS for the PET/CT group (27.1 months; 95% CI: 21.9&#x02013;32.3 months) was markedly higher than that for the CT group (18.9 months; 95% CI: 14.7&#x02013;23.1 months) (<italic>P</italic>=0.019). The cumulative 1-year, 2-year, and 3-year DFS rates were 78.3%, 49.2%, and 32.5% in the PET/CT group versus 62.6%, 26.3%, and 14.4% in the CT group, respectively (<xref ref-type="fig" rid="f2-ott-9-855">Figure 2</xref>). Subgroup analysis of node-positive patients indicates that the PET/CT group again demonstrates longer mean DFS (22.5 months; 95% CI: 17.4&#x02013;27.6 months versus 13.5 months; 95% CI: 9.6&#x02013;17.5 months) (<italic>P</italic>=0.02; <xref ref-type="fig" rid="f3-ott-9-855">Figure 3</xref>).</p><p>Among the factors influencing DFS, pathological staging, therapeutic modality, operative features (curative or palliative), and preoperative imaging (the grouping factor) showed <italic>P</italic>-values &#x0003c;0.1 on univariate analysis (<xref ref-type="table" rid="t1-ott-9-855">Table 1</xref>). The multivariate analysis with Cox regression model revealed that preoperative imaging modality was the only independent significant predictor for DFS.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Lymphatic metastasis is relatively frequent in EC, especially once the tumor involves the submucosal layer, and evaluation of nodal status is quite important before surgery.<xref rid="b12-ott-9-855" ref-type="bibr">12</xref>,<xref rid="b18-ott-9-855" ref-type="bibr">18</xref> CT suggests clinical nodal status based only on size criteria, and, as a result, the accuracy is limited.<xref rid="b3-ott-9-855" ref-type="bibr">3</xref>,<xref rid="b15-ott-9-855" ref-type="bibr">15</xref>,<xref rid="b20-ott-9-855" ref-type="bibr">20</xref>,<xref rid="b21-ott-9-855" ref-type="bibr">21</xref> FDG-PET detects alterations in tissue metabolism.<xref rid="b22-ott-9-855" ref-type="bibr">22</xref> Therefore, FDG-PET appears to be more accurate than CT, especially when PET images are fused with CT images.<xref rid="b23-ott-9-855" ref-type="bibr">23</xref>&#x02013;<xref rid="b26-ott-9-855" ref-type="bibr">26</xref></p><p>This study confirms both the greater sensitivity and accuracy of PET/CT than CT in detecting LN metastasis in patients with EC. The specificity of the two modalities was similar. Several other reports have also confirmed the advantage of PET/CT in the detection of LN metastasis for patients with EC.<xref rid="b13-ott-9-855" ref-type="bibr">13</xref>&#x02013;<xref rid="b15-ott-9-855" ref-type="bibr">15</xref>,<xref rid="b18-ott-9-855" ref-type="bibr">18</xref>,<xref rid="b19-ott-9-855" ref-type="bibr">19</xref>,<xref rid="b27-ott-9-855" ref-type="bibr">27</xref>,<xref rid="b28-ott-9-855" ref-type="bibr">28</xref> One prospective study revealed that the sensitivity, specificity, and accuracy of PET/CT were 76.19%, 95.93%, and 93.06%, respectively, whereas those of CT were 33.33%, 94.31%, and 85.42%, respectively (<italic>P</italic>-values: 0.0117, 0.7539, and 0.0266, respectively).<xref rid="b29-ott-9-855" ref-type="bibr">29</xref> Furthermore, it would appear from our results that the improved detection of nodal metastasis with PET/CT resulted in our surgeons removing more involved nodal groups in the PET/CT group.</p><p>We performed the Ivor Lewis procedure, instead of left thoracotomy, only when imaging findings suggested the presence of LNs that would not be removable by the left-sided approach. Owing to the additional detection of metastatic nodes within the right mediastinum, 42.6% of the patents in the PET/CT group versus 25.5% of the patents in the CT group underwent the right-sided operation.</p><p>The increased number of involved LNs and LN stations dissected in the PET/CT group may have important therapeutic implications. The DFS was significantly improved in the PET/CT group. This may have resulted from the fact that the PET/CT-directed operation increased the likelihood of proper staging and thereby directed appropriate postoperative therapy more accurately.<xref rid="b28-ott-9-855" ref-type="bibr">28</xref>,<xref rid="b30-ott-9-855" ref-type="bibr">30</xref>,<xref rid="b31-ott-9-855" ref-type="bibr">31</xref> Alternatively, the improved DFS may have resulted from more complete excision of involved LNs in the PET/CT group. In &#x0003e;40% of cases with EC, the first recurrence after surgery occurs within the regional LNs,<xref rid="b32-ott-9-855" ref-type="bibr">32</xref> and consequently, complete nodal resection may affect postoperative survival. Adjuvant therapy and pathological staging can also pose an impact on survival. However, as demonstrated in <xref ref-type="table" rid="t1-ott-9-855">Table 1</xref>, there were no differences in case distributions between the PET/CT and CT group. It is reasonable to conclude that the DFS advantage in the PET/CT group was due to a relatively complete resection guided by PET/CT imaging.</p><p>Basing more extensive (right-sided) resection of LNs upon preoperative PET/CT imaging was an independent prognostic factor in DFS. Therefore, it is quite likely that the improved DFS observed in the PET/CT group was due to the increase in the removal of positive LNs. Further subgroup analysis of N+ patients also confirmed this point (<xref ref-type="fig" rid="f3-ott-9-855">Figure 3</xref>).</p><p>It is generally acknowledged that the increased number of invaded LNs indicates a poorer prognosis.<xref rid="b32-ott-9-855" ref-type="bibr">32</xref> However, our data interestingly revealed that patients with more invaded nodes through PET/CT-based nodal resection had an equivalent OS and improved DFS.</p><p>It may appear possibly on the first glance that our study shows improved LN yield and DFS in the PET/CT group only by virtue of the fact that the PET/CT group had a greater percentage of patients undergoing right- versus left-sided approaches. In other words, one might argue that perhaps all we have demonstrated is that the Ivor Lewis approach is superior from an oncological point of view to the left-sided thoracotomy alone approach. However, the results of the multivariate analysis of factors influencing DFS, which identified imaging modality and not thoracotomy (transthoracic approach; <xref ref-type="table" rid="t1-ott-9-855">Table 1</xref>) as a significant factor, do not support this line of reasoning. Additionally, the left-sided thoracotomy alone approach is both simpler to carry out (no repositioning) and (we believe) less morbid. Therefore, we believe that it is ideal to reserve the right-sided approach and more extensive lymphadenectomy for patients in whom this is indicated by imaging-demonstrated nodal involvement. Our low complication and mortality rates bear out the reasonableness of this approach.</p></sec><sec><title>Conclusion</title><p>We confirm the increased accuracy of PET/CT versus CT for LN involvement in EC. Furthermore, we find that PET/CT is useful in determining those patients who will benefit from a right-sided approach with more extensive LN resection. Patients who underwent preoperative PET/CT evaluation and consequent image-directed surgical approach had an improved DFS versus those having CT alone, while still allowing many patients to undergo a less morbid approach with a less radical lymphadenectomy. Surgery directed by PET/CT, as described here, appears to represent a reasonable compromise between routine, extensive LN dissection (eg, three-field lymphadenectomy) and minimally invasive surgical procedures with lesser lymphadenectomy (eg, transhiatal approach).</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by Grant no ZR2011HL029 from the Natural Science Foundation of Shandong Province to Hongbo Guo.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors have no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ott-9-855"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downey</surname><given-names>RJ</given-names></name><name><surname>Akhurst</surname><given-names>T</given-names></name><name><surname>Ilson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><issue>3</issue><fpage>428</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">12560430</pub-id></element-citation></ref><ref id="b2-ott-9-855"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Sueyoshi</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy</article-title><source>World J Surg</source><year>2003</year><volume>27</volume><issue>5</issue><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">12715226</pub-id></element-citation></ref><ref id="b3-ott-9-855"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rustgi</surname><given-names>AK</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name></person-group><article-title>Esophageal carcinoma</article-title><source>N Engl J Med</source><year>2014</year><volume>371</volume><issue>26</issue><fpage>2499</fpage><lpage>2509</lpage><pub-id pub-id-type="pmid">25539106</pub-id></element-citation></ref><ref id="b4-ott-9-855"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiranyatheb</surname><given-names>P</given-names></name><name><surname>Osugi</surname><given-names>H</given-names></name></person-group><article-title>Radical lymphadenectomy in esophageal cancer: from the past to the present</article-title><source>Dis Esophagus</source><year>2015</year><volume>28</volume><issue>1</issue><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">23796327</pub-id></element-citation></ref><ref id="b5-ott-9-855"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dresner</surname><given-names>SM</given-names></name><name><surname>Griffin</surname><given-names>SM</given-names></name></person-group><article-title>Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy</article-title><source>Br J Surg</source><year>2000</year><volume>87</volume><issue>10</issue><fpage>1426</fpage><lpage>1433</lpage><pub-id pub-id-type="pmid">11044172</pub-id></element-citation></ref><ref id="b6-ott-9-855"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Okazumi</surname><given-names>S</given-names></name><name><surname>Matsubara</surname><given-names>H</given-names></name><etal/></person-group><article-title>Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection</article-title><source>World J Surg</source><year>2006</year><volume>30</volume><issue>8</issue><fpage>1441</fpage><lpage>1449</lpage><pub-id pub-id-type="pmid">16871357</pub-id></element-citation></ref><ref id="b7-ott-9-855"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>DW</given-names></name><name><surname>Cheng</surname><given-names>GY</given-names></name><name><surname>Huang</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Operable squamous esophageal cancer: current results from the East</article-title><source>World J Surg</source><year>1994</year><volume>18</volume><issue>3</issue><fpage>347</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">8091774</pub-id></element-citation></ref><ref id="b8-ott-9-855"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>A</given-names></name></person-group><article-title>Operable esophageal cancer: current results from the West</article-title><source>World J Surg</source><year>1994</year><volume>18</volume><issue>3</issue><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">8091776</pub-id></element-citation></ref><ref id="b9-ott-9-855"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulscher</surname><given-names>JB</given-names></name><name><surname>Tijssen</surname><given-names>JG</given-names></name><name><surname>Obertop</surname><given-names>H</given-names></name><name><surname>van Lanschot</surname><given-names>JJ</given-names></name></person-group><article-title>Transthoracic versus transhiatal resection for carcinoma of the esophagus: a meta-analysis</article-title><source>Ann Thorac Surg</source><year>2001</year><volume>72</volume><issue>1</issue><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">11465217</pub-id></element-citation></ref><ref id="b10-ott-9-855"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantoc</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>MR</given-names></name><name><surname>Eslick</surname><given-names>GD</given-names></name></person-group><article-title>Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis</article-title><source>Arch Surg</source><year>2012</year><volume>147</volume><issue>8</issue><fpage>768</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">22911078</pub-id></element-citation></ref><ref id="b11-ott-9-855"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Ando</surname><given-names>N</given-names></name><etal/></person-group><article-title>Validation study of radio-guided sentinel lymph node navigation in esophageal cancer</article-title><source>Ann Surg</source><year>2009</year><volume>249</volume><issue>5</issue><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="pmid">19387329</pub-id></element-citation></ref><ref id="b12-ott-9-855"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Shim</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET</article-title><source>J Nucl Med</source><year>2000</year><volume>41</volume><issue>5</issue><fpage>808</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">10809196</pub-id></element-citation></ref><ref id="b13-ott-9-855"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flamen</surname><given-names>P</given-names></name><name><surname>Lerut</surname><given-names>A</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><etal/></person-group><article-title>Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><issue>18</issue><fpage>3202</fpage><lpage>3210</lpage><pub-id pub-id-type="pmid">10986052</pub-id></element-citation></ref><ref id="b14-ott-9-855"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma</article-title><source>Cancer</source><year>2002</year><volume>94</volume><issue>4</issue><fpage>921</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">11920459</pub-id></element-citation></ref><ref id="b15-ott-9-855"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Vliet</surname><given-names>EP</given-names></name><name><surname>Heijenbrok-Kal</surname><given-names>MH</given-names></name><name><surname>Hunink</surname><given-names>MG</given-names></name><name><surname>Kuipers</surname><given-names>EJ</given-names></name><name><surname>Siersema</surname><given-names>PD</given-names></name></person-group><article-title>Staging investigations for oesophageal cancer: a meta-analysis</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><issue>3</issue><fpage>547</fpage><lpage>557</lpage><pub-id pub-id-type="pmid">18212745</pub-id></element-citation></ref><ref id="b16-ott-9-855"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lightdale</surname><given-names>CJ</given-names></name></person-group><article-title>Positron emission tomography: another useful test for staging esophageal cancer</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><issue>18</issue><fpage>3199</fpage><lpage>3201</lpage><pub-id pub-id-type="pmid">10986051</pub-id></element-citation></ref><ref id="b17-ott-9-855"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>EA</given-names></name><name><surname>Farmer</surname><given-names>MR</given-names></name><name><surname>Clark</surname><given-names>P</given-names></name><etal/></person-group><article-title>Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer</article-title><source>Ann Surg</source><year>2006</year><volume>243</volume><issue>4</issue><fpage>472</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">16552197</pub-id></element-citation></ref><ref id="b18-ott-9-855"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerut</surname><given-names>T</given-names></name><name><surname>Flamen</surname><given-names>P</given-names></name><name><surname>Ectors</surname><given-names>N</given-names></name><etal/></person-group><article-title>Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy</article-title><source>Ann Surg</source><year>2000</year><volume>232</volume><issue>6</issue><fpage>743</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">11088069</pub-id></element-citation></ref><ref id="b19-ott-9-855"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karashima</surname><given-names>R</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer</article-title><source>Surg Today</source><year>2015</year><volume>45</volume><issue>4</issue><fpage>471</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">24969050</pub-id></element-citation></ref><ref id="b20-ott-9-855"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Fukuchi</surname><given-names>M</given-names></name><name><surname>Manda</surname><given-names>R</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name></person-group><article-title>Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma</article-title><source>Br J Surg</source><year>2004</year><volume>91</volume><issue>8</issue><fpage>1004</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">15286962</pub-id></element-citation></ref><ref id="b21-ott-9-855"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flamen</surname><given-names>P</given-names></name><name><surname>Lerut</surname><given-names>A</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><etal/></person-group><article-title>The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer</article-title><source>J Thorac Cardiovasc Surg</source><year>2000</year><volume>120</volume><issue>6</issue><fpage>1085</fpage><lpage>1092</lpage><pub-id pub-id-type="pmid">11088030</pub-id></element-citation></ref><ref id="b22-ott-9-855"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poeppel</surname><given-names>TD</given-names></name><name><surname>Krause</surname><given-names>BJ</given-names></name><name><surname>Heusner</surname><given-names>TA</given-names></name><name><surname>Boy</surname><given-names>C</given-names></name><name><surname>Bockisch</surname><given-names>A</given-names></name><name><surname>Antoch</surname><given-names>G</given-names></name></person-group><article-title>PET/CT for the staging and follow-up of patients with malignancies</article-title><source>Eur J Radiol</source><year>2009</year><volume>70</volume><issue>3</issue><fpage>382</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">19406595</pub-id></element-citation></ref><ref id="b23-ott-9-855"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyer</surname><given-names>T</given-names></name><name><surname>Townsend</surname><given-names>DW</given-names></name><name><surname>Brun</surname><given-names>T</given-names></name><etal/></person-group><article-title>A combined PET/CT scanner for clinical oncology</article-title><source>J Nucl Med</source><year>2000</year><volume>41</volume><issue>8</issue><fpage>1369</fpage><lpage>1379</lpage><pub-id pub-id-type="pmid">10945530</pub-id></element-citation></ref><ref id="b24-ott-9-855"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar-Shalom</surname><given-names>R</given-names></name><name><surname>Guralnik</surname><given-names>L</given-names></name><name><surname>Tsalic</surname><given-names>M</given-names></name><etal/></person-group><article-title>The additional value of PET/CT over PET in FDG imaging of oesophageal cancer</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2005</year><volume>32</volume><issue>8</issue><fpage>918</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">15838691</pub-id></element-citation></ref><ref id="b25-ott-9-855"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus</article-title><source>J Nucl Med</source><year>2007</year><volume>48</volume><issue>8</issue><fpage>1251</fpage><lpage>1258</lpage><pub-id pub-id-type="pmid">17631554</pub-id></element-citation></ref><ref id="b26-ott-9-855"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><etal/></person-group><article-title>The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer</article-title><source>Oncol Rep</source><year>2008</year><volume>20</volume><issue>4</issue><fpage>857</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">18813827</pub-id></element-citation></ref><ref id="b27-ott-9-855"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>MI</given-names></name><name><surname>Patterson</surname><given-names>GA</given-names></name><name><surname>Sundaresan</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Improvement in staging of esophageal cancer with the addition of positron emission tomography</article-title><source>Ann Thorac Surg</source><year>1997</year><volume>64</volume><issue>3</issue><fpage>770</fpage><lpage>776</lpage><comment>discussion 776&#x02013;777</comment><pub-id pub-id-type="pmid">9307472</pub-id></element-citation></ref><ref id="b28-ott-9-855"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Westreenen</surname><given-names>HL</given-names></name><name><surname>Westerterp</surname><given-names>M</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><issue>18</issue><fpage>3805</fpage><lpage>3812</lpage><pub-id pub-id-type="pmid">15365078</pub-id></element-citation></ref><ref id="b29-ott-9-855"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Fu</surname><given-names>XL</given-names></name><name><surname>Zhang</surname><given-names>YJ</given-names></name><name><surname>Xiang</surname><given-names>JQ</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name></person-group><article-title>A prospective evaluation of staging and target volume definition of lymph nodes by <sup>18</sup>FDG PET/CT in patients with squamous cell carcinoma of thoracic esophagus</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2011</year><volume>81</volume><issue>5</issue><fpage>e759</fpage><lpage>e765</lpage><pub-id pub-id-type="pmid">21470788</pub-id></element-citation></ref><ref id="b30-ott-9-855"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>T</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><etal/></person-group><article-title>The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma</article-title><source>Cancer</source><year>2005</year><volume>103</volume><issue>1</issue><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">15558794</pub-id></element-citation></ref><ref id="b31-ott-9-855"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>JJ</given-names></name><name><surname>Wong</surname><given-names>RK</given-names></name><name><surname>Darling</surname><given-names>G</given-names></name><name><surname>Gulenchyn</surname><given-names>K</given-names></name><name><surname>Urbain</surname><given-names>JL</given-names></name><name><surname>Evans</surname><given-names>WK</given-names></name></person-group><article-title>Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer</article-title><source>J Thorac Oncol</source><year>2013</year><volume>8</volume><issue>12</issue><fpage>1563</fpage><lpage>1569</lpage><pub-id pub-id-type="pmid">24389439</pub-id></element-citation></ref><ref id="b32-ott-9-855"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mariette</surname><given-names>C</given-names></name><name><surname>Piessen</surname><given-names>G</given-names></name><name><surname>Briez</surname><given-names>N</given-names></name><name><surname>Triboulet</surname><given-names>JP</given-names></name></person-group><article-title>The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent</article-title><source>Ann Surg</source><year>2008</year><volume>247</volume><issue>2</issue><fpage>365</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">18216546</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ott-9-855" position="float"><label>Figure 1</label><caption><p>Whole-body fusion PET/CT imaging for a 58-year-old male with squamous carcinoma of the lower thoracic esophagus at biopsy.</p><p><bold>Notes:</bold> Increased FDG accumulation exhibited at the esophagus with a SUVmax of 11.9, a positive lymph node adjacent to trachea, measuring 0.6 cm in short-axis diameter (SUV =5.6), was confirmed as malignant on pathology. Since PET/CT showed the positive node at the right-upper mediastinum, a right thoracotomy, instead of left transthoracic approach which was routinely used for the lower EC, was performed.</p><p><bold>Abbreviations:</bold> SUV, standardized uptake value; PET, positron emission tomography; CT, computed tomography; FDG, fluorine-18 fluorodeoxyglucose.</p></caption><graphic xlink:href="ott-9-855Fig1"/></fig><fig id="f2-ott-9-855" position="float"><label>Figure 2</label><caption><p>Kaplan&#x02013;Meier curves of DFS for the two groups (PET/CT and CT group).</p><p><bold>Abbreviations:</bold> CT, computed tomography; PET, positron emission tomography; DFS, disease-free survival.</p></caption><graphic xlink:href="ott-9-855Fig2"/></fig><fig id="f3-ott-9-855" position="float"><label>Figure 3</label><caption><p>Kaplan&#x02013;Meier curves of DFS for the subgroup of positive lymph nodes patients (PET/CT and CT group).</p><p><bold>Abbreviations:</bold> CT, computed tomography; PET, positron emission tomography; DFS, disease-free survival.</p></caption><graphic xlink:href="ott-9-855Fig3"/></fig><table-wrap id="t1-ott-9-855" position="float"><label>Table 1</label><caption><p>Characteristics of patients and results of survival analysis for predicting DFS</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Characteristics</th><th colspan="2" valign="top" align="left" rowspan="1">N
<hr/></th><th colspan="2" valign="top" align="left" rowspan="1">Univariate analysis
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>P</italic>-value</th><th colspan="2" valign="top" align="left" rowspan="1">Multivariate analysis
<hr/></th><th rowspan="2" valign="top" align="left" colspan="1"><italic>P</italic>-value</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">PET</th><th valign="top" align="left" rowspan="1" colspan="1">CT</th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1">HR</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age<xref ref-type="table-fn" rid="tfn1-ott-9-855">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.998</td><td valign="top" align="left" rowspan="1" colspan="1">0.972&#x02013;1.024</td><td valign="top" align="left" rowspan="1" colspan="1">0.842</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Sex</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Male</td><td valign="top" align="left" rowspan="1" colspan="1">46</td><td valign="top" align="left" rowspan="1" colspan="1">40</td><td valign="top" align="left" rowspan="1" colspan="1">1.133</td><td valign="top" align="left" rowspan="1" colspan="1">0.578&#x02013;2.223</td><td valign="top" align="left" rowspan="1" colspan="1">0.716</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Female<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Tumor location</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Lower</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">19</td><td valign="top" align="left" rowspan="1" colspan="1">0.954</td><td valign="top" align="left" rowspan="1" colspan="1">0.574&#x02013;1.587</td><td valign="top" align="left" rowspan="1" colspan="1">0.857</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Middle<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">36</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Tumor differentiation</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Well</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">0.744</td><td valign="top" align="left" rowspan="1" colspan="1">0.404&#x02013;1.371</td><td valign="top" align="left" rowspan="1" colspan="1">0.343</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">28</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">0.87</td><td valign="top" align="left" rowspan="1" colspan="1">0.456&#x02013;1.663</td><td valign="top" align="left" rowspan="1" colspan="1">0.674</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Poor<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Therapeutic modality</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Surgery alone</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">1.857</td><td valign="top" align="left" rowspan="1" colspan="1">0.869&#x02013;3.968</td><td valign="top" align="left" rowspan="1" colspan="1">0.110</td><td valign="top" align="left" rowspan="1" colspan="1">1.630</td><td valign="top" align="left" rowspan="1" colspan="1">0.737&#x02013;3.603</td><td valign="top" align="left" rowspan="1" colspan="1">0.228</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Plus chemoradiation</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">22</td><td valign="top" align="left" rowspan="1" colspan="1">2.207</td><td valign="top" align="left" rowspan="1" colspan="1">1.177&#x02013;4.138</td><td valign="top" align="left" rowspan="1" colspan="1">0.014</td><td valign="top" align="left" rowspan="1" colspan="1">1.852</td><td valign="top" align="left" rowspan="1" colspan="1">0.949&#x02013;3.614</td><td valign="top" align="left" rowspan="1" colspan="1">0.071</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Plus chemotherapy<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Surgery</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Curative surgery</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="left" rowspan="1" colspan="1">0.440</td><td valign="top" align="left" rowspan="1" colspan="1">0.2&#x02013;0.969</td><td valign="top" align="left" rowspan="1" colspan="1">0.042</td><td valign="top" align="left" rowspan="1" colspan="1">0.523</td><td valign="top" align="left" rowspan="1" colspan="1">0.208&#x02013;1.315</td><td valign="top" align="left" rowspan="1" colspan="1">0.168</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Palliative surgery<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Pathological stages</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IIa</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">0.272</td><td valign="top" align="left" rowspan="1" colspan="1">0.101&#x02013;0.732</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.378</td><td valign="top" align="left" rowspan="1" colspan="1">0.138&#x02013;1.030</td><td valign="top" align="left" rowspan="1" colspan="1">0.057</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IIb</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">0.060</td><td valign="top" align="left" rowspan="1" colspan="1">0.007&#x02013;0.502</td><td valign="top" align="left" rowspan="1" colspan="1">0.009</td><td valign="top" align="left" rowspan="1" colspan="1">0.089</td><td valign="top" align="left" rowspan="1" colspan="1">0.317&#x02013;1.373</td><td valign="top" align="left" rowspan="1" colspan="1">0.088</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;III</td><td valign="top" align="left" rowspan="1" colspan="1">36</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="left" rowspan="1" colspan="1">0.459</td><td valign="top" align="left" rowspan="1" colspan="1">0.194&#x02013;1.087</td><td valign="top" align="left" rowspan="1" colspan="1">0.077</td><td valign="top" align="left" rowspan="1" colspan="1">0.563</td><td valign="top" align="left" rowspan="1" colspan="1">0.236&#x02013;1.342</td><td valign="top" align="left" rowspan="1" colspan="1">0.195</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;IV<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Thoractomy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Right thoractomy</td><td valign="top" align="left" rowspan="1" colspan="1">23</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">1.280</td><td valign="top" align="left" rowspan="1" colspan="1">0.777&#x02013;2.107</td><td valign="top" align="left" rowspan="1" colspan="1">0.332</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Left thoractomy<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">31</td><td valign="top" align="left" rowspan="1" colspan="1">38</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="9" valign="top" align="left" rowspan="1">Preoperative imaging</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PET/CT</td><td valign="top" align="left" rowspan="1" colspan="1">54</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">0.566</td><td valign="top" align="left" rowspan="1" colspan="1">0.347&#x02013;0.923</td><td valign="top" align="left" rowspan="1" colspan="1">0.023</td><td valign="top" align="left" rowspan="1" colspan="1">0.568</td><td valign="top" align="left" rowspan="1" colspan="1">0.355&#x02013;0.970</td><td valign="top" align="left" rowspan="1" colspan="1">0.038</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;CT<xref ref-type="table-fn" rid="tfn2-ott-9-855">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-ott-9-855"><label>a</label><p>Continuous variable.</p></fn><fn id="tfn2-ott-9-855"><label>b</label><p>Reference.</p></fn><fn id="tfn3-ott-9-855"><p><bold>Abbreviations:</bold> CT, computed tomography; DFS, disease-free survival; HR, hazard ratio; PET, positron emission tomography.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ott-9-855" position="float"><label>Table 2</label><caption><p>Comparison of operative procedures between the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Tumor location</th><th valign="top" align="left" rowspan="1" colspan="1">Operative procedures</th><th valign="top" align="left" rowspan="1" colspan="1">PET/CT group (n)</th><th valign="top" align="left" rowspan="1" colspan="1">CT group (n)</th><th valign="top" align="left" rowspan="1" colspan="1">Total (n)</th></tr></thead><tbody><tr><td rowspan="3" valign="top" align="left" colspan="1">Middle segment</td><td valign="top" align="left" rowspan="1" colspan="1">Left thoracotomy</td><td valign="top" align="left" rowspan="1" colspan="1">22<xref ref-type="table-fn" rid="tfn4-ott-9-855">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">46</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ivor Lewis procedure</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mckeown procedure</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">5</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Lower segment</td><td valign="top" align="left" rowspan="1" colspan="1">Left thoracotomy</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">23</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ivor Lewis procedure</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mckeown procedure</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">54</td><td valign="top" align="left" rowspan="1" colspan="1">51</td><td valign="top" align="left" rowspan="1" colspan="1">105</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn4-ott-9-855"><label>a</label><p>One patient underwent left thoracotomy instead of right thoracic approach because of low pulmonary function.</p></fn><fn id="tfn5-ott-9-855"><p><bold>Abbreviations:</bold> CT, computed tomography; PET, positron emission tomography.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ott-9-855" position="float"><label>Table 3</label><caption><p>Comparison of results of nodal resection between the two groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"/><th colspan="3" valign="top" align="left" rowspan="1">Number of resected nodes
<hr/></th><th colspan="3" valign="top" align="left" rowspan="1">Number of nodal stations removed
<hr/></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">PET/CT</th><th valign="top" align="left" rowspan="1" colspan="1">CT</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th valign="top" align="left" rowspan="1" colspan="1">PET/CT</th><th valign="top" align="left" rowspan="1" colspan="1">CT</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Total LNs</td><td valign="top" align="left" rowspan="1" colspan="1">19.59</td><td valign="top" align="left" rowspan="1" colspan="1">17.57</td><td valign="top" align="left" rowspan="1" colspan="1">0.088</td><td valign="top" align="left" rowspan="1" colspan="1">6.91</td><td valign="top" align="left" rowspan="1" colspan="1">7.02</td><td valign="top" align="left" rowspan="1" colspan="1">0.724</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mediastinal</td><td valign="top" align="left" rowspan="1" colspan="1">11.37</td><td valign="top" align="left" rowspan="1" colspan="1">10.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.114</td><td valign="top" align="left" rowspan="1" colspan="1">4.09</td><td valign="top" align="left" rowspan="1" colspan="1">4.16</td><td valign="top" align="left" rowspan="1" colspan="1">0.788</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal</td><td valign="top" align="left" rowspan="1" colspan="1">8.17</td><td valign="top" align="left" rowspan="1" colspan="1">7.35</td><td valign="top" align="left" rowspan="1" colspan="1">0.239</td><td valign="top" align="left" rowspan="1" colspan="1">2.78</td><td valign="top" align="left" rowspan="1" colspan="1">2.84</td><td valign="top" align="left" rowspan="1" colspan="1">0.737</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Involved LNs</td><td valign="top" align="left" rowspan="1" colspan="1">2.83</td><td valign="top" align="left" rowspan="1" colspan="1">1.76</td><td valign="top" align="left" rowspan="1" colspan="1">0.039</td><td valign="top" align="left" rowspan="1" colspan="1">1.65</td><td valign="top" align="left" rowspan="1" colspan="1">1.08</td><td valign="top" align="left" rowspan="1" colspan="1">0.042</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mediastinal</td><td valign="top" align="left" rowspan="1" colspan="1">2.06</td><td valign="top" align="left" rowspan="1" colspan="1">1.31</td><td valign="top" align="left" rowspan="1" colspan="1">0.078</td><td valign="top" align="left" rowspan="1" colspan="1">1.15</td><td valign="top" align="left" rowspan="1" colspan="1">0.76</td><td valign="top" align="left" rowspan="1" colspan="1">0.083</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal</td><td valign="top" align="left" rowspan="1" colspan="1">0.72</td><td valign="top" align="left" rowspan="1" colspan="1">0.43</td><td valign="top" align="left" rowspan="1" colspan="1">0.129</td><td valign="top" align="left" rowspan="1" colspan="1">0.46</td><td valign="top" align="left" rowspan="1" colspan="1">0.29</td><td valign="top" align="left" rowspan="1" colspan="1">0.168</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Invaded nodes<xref ref-type="table-fn" rid="tfn6-ott-9-855">a</xref></td><td valign="top" align="left" rowspan="1" colspan="1">21.5%</td><td valign="top" align="left" rowspan="1" colspan="1">18.1%</td><td valign="top" align="left" rowspan="1" colspan="1">0.148</td><td valign="top" align="left" rowspan="1" colspan="1">36.3%</td><td valign="top" align="left" rowspan="1" colspan="1">27.9%</td><td valign="top" align="left" rowspan="1" colspan="1">0.038</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn6-ott-9-855"><label>a</label><p>Percentage of invaded lymph nodes among totally removed from positive lymph nodes patients.</p></fn><fn id="tfn7-ott-9-855"><p><bold>Abbreviations:</bold> CT, computed tomography; LNs, lymph nodes; PET, positron emission tomography.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ott-9-855" position="float"><label>Table 4</label><caption><p>Comparison of PET/CT and CT by different methods</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">PET/CT</th><th valign="top" align="left" rowspan="1" colspan="1">CT</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Total resected LNs, n</td><td valign="top" align="left" rowspan="1" colspan="1">1,058</td><td valign="top" align="left" rowspan="1" colspan="1">896</td><td valign="top" align="left" rowspan="1" colspan="1">0.430</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">True positive, n</td><td valign="top" align="left" rowspan="1" colspan="1">153</td><td valign="top" align="left" rowspan="1" colspan="1">90</td><td valign="top" align="left" rowspan="1" colspan="1">0.007</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sensitivity</td><td valign="top" align="left" rowspan="1" colspan="1">86.5%</td><td valign="top" align="left" rowspan="1" colspan="1">76.3%</td><td valign="top" align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Accuracy</td><td valign="top" align="left" rowspan="1" colspan="1">92.2%</td><td valign="top" align="left" rowspan="1" colspan="1">87.2%</td><td valign="top" align="left" rowspan="1" colspan="1">0.024</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Specificity</td><td valign="top" align="left" rowspan="1" colspan="1">94.0%</td><td valign="top" align="left" rowspan="1" colspan="1">90.8%</td><td valign="top" align="left" rowspan="1" colspan="1">0.139</td></tr></tbody></table><table-wrap-foot><fn id="tfn8-ott-9-855"><p><bold>Abbreviations:</bold> CT, computed tomography; LNs, lymph nodes; PET, positron emission tomography.</p></fn></table-wrap-foot></table-wrap></floats-group></article>